Technische Universität Dresden
tu-dresden.deTotal trials
246
Active
49
Phase 3
21
Total enrollment
2,022,177
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 23 of 23 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | 4 | ||
| Venetoclax | — | — | — | — | — | 2 | |
| MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO | — | — | — | — | — | 1 | |
| MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO | — | — | — | — | — | 1 | |
| MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO | — | — | — | — | — | 1 | |
| MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin | — | — | — | — | — | 1 | |
| MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin | — | — | — | — | — | 1 | |
| Treosulfan | — | — | — | — | — | 1 | |
| Melphalan | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 | |
| Ivosidenib 250 MG | — | — | — | — | — | 1 | |
| Venetoclax plus Azacitidine | — | — | — | — | — | 1 | |
| standard of care chemotherapy plus gemtuzumab ozogamicin | — | — | — | — | — | 1 | |
| Gilteritinib | — | — | — | — | — | 1 | |
| Obrixtamig | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| MDC-CAR-BCMA001 | — | — | — | — | — | 1 | |
| fMRI imaging | — | — | — | — | — | 1 | |
| sMRI | — | — | — | — | — | 1 | |
| Upadacitinib | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 |
Next readouts
- 2023-06
- 2025-12-31
- 2027-04
- 2027-06
- 2027-06-30
- 2028-01
- 2028-01-31
- 2028-09
- 2028-12
- 2029-04
Top conditions
- Glaucoma7
- Acute Myeloid Leukemia7
- Alcoholism7
- Atopic Dermatitis5
- Healthy Subjects5
- Knee Osteoarthritis5
- Myelodysplastic Syndromes4
- Colorectal Cancer4
Frequently asked questions about Technische Universität Dresden
- How many clinical trials does Technische Universität Dresden have on ClinicalTrials.gov?
- Technische Universität Dresden is listed as the lead sponsor on 246 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Technische Universität Dresden's trials are in Phase 3?
- 21 of Technische Universität Dresden's trials are in Phase 3, spread across 23 active drug programs.
- What therapeutic areas does Technische Universität Dresden focus on?
- Technische Universität Dresden's most-studied conditions on ClinicalTrials.gov are Glaucoma, Acute Myeloid Leukemia, Alcoholism, Atopic Dermatitis, Healthy Subjects.
- When are Technische Universität Dresden's next clinical trial readouts?
- Technische Universität Dresden has 10 upcoming primary-completion readouts tracked here; the soonest is “Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation”, expected around 2023-06.